Correlation Engine 2.0
Clear Search sequence regions


  • clenbuterol (5)
  • corticosteroid (1)
  • drug ms (1)
  • drug residues (2)
  • liver (1)
  • liver extracts (1)
  • mass (1)
  • safety (1)
  • screen (1)
  • steroids (1)
  • Sizes of these terms reflect their relevance to your search.

    Surveillance of illegal use of growth promoters such as β2-agonists in food producing animals rely on the detection of drug residues by LC-MS/MS. Screening strategies focusing on indirect physiological responses following administration of active compounds are promising approaches to strengthen existing targeted methods and ensure food safety. A metabolomics analysis based on LC-HRMS was carried out on liver extracts from bulls experimentally treated with clenbuterol combined with dexamethasone (n = 8) to mimic a potential anabolic practice, and control animals (n = 8). Nicotinic acid and 5'-deoxy-5'-methylthioadenosine were identified as biomarkers of treatment. Ratio values of such markers to others of the same metabolic pathways (nicotinamide or methionine) were used to develop a classification model to assign animals as treated with clenbuterol or non-treated. The classification model was tested on an external validation set comprising 74 animals either treated with different anabolic compounds (β2-agonists, sexual steroids, corticosteroid), or non-treated, showing 100% sensitivity and specificity. Copyright © 2021 Elsevier Ltd. All rights reserved.

    Citation

    Roberto Stella, Davide Bovo, Eleonora Mastrorilli, Elisabetta Manuali, Marzia Pezzolato, Elena Bozzetta, Francesca Lega, Roberto Angeletti, Giancarlo Biancotto. A novel tool to screen for treatments with clenbuterol in bovine: Identification of two hepatic markers by metabolomics investigation. Food chemistry. 2021 Aug 15;353:129366

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33838430

    View Full Text